Treating human autoimmunity: Current practice and future prospects

Science Translational Medicine

Volumn 4, Issue 125, 2012, Pages

  Rosenblum, Michael D ^a   Gratz, Iris K ^a   Paw, Jonathan S ^a   Abbas, Abul K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AMG 557; ANTIDIABETIC AGENT; AZACITIDINE; BG 9588; CD28 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIAPEP277; EFALIZUMAB; FORIGERIMOD; GLUTAMATE DECARBOXYLASE 65; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOCYTE ANTIGEN; METHOTREXATE; PLACEBO; RAPAMYCIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; TGN 1412; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALOPECIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; DESENSITIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY;

EID: 84858307154     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003504     Document Type: Review

References (67)

1. American Autoimmune Related Diseases Association, The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending (American Autoimmune Related Diseases Association, East Detroit, MI, 2011); http://www.aarda.org/infocus-article.php?ID=74.
2. S. J. Walsh, L. M. Rau, Autoimmune diseases: A leading cause of death among young and middle-aged women in the United States. Am. J. Public Health 90, 1463-1466 (2000).
3. M. M. Davis, J. D. Altman, E. W. Newell, Interrogating the repertoire: Broadening the scope of peptide - MHC multimer analysis. Nat. Rev. Immunol. 11, 551-558 (2011).
4. D. L. Mueller, Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11, 21-27 (2010).
5. D. J. Lenschow, Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, J. A. Bluestone, Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789-792 (1992).
6. L. J. Maxwell, J. A. Singh, Abatacept for rheumatoid arthritis: A Cochrane systematic review. J. Rheumatol. 37, 234-245 (2010).
7. P. Mease, M. C. Genovese, G. Gladstein, A. J. Kivitz, C. Ritchlin, P. P. Tak, J. Wollenhaupt, O. Bahary, J. C. Becker, S. Kelly, L. Sigal, J. Teng, D. Gladman, Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 63, 939-948 (2011).
8. T. Orban, B. Bundy, D. J. Becker, L. A. DiMeglio, S. E. Gitelman, R. Goland, P. A. Gottlieb, C. J. Greenbaum, J. B. Marks, R. Monzavi, A. Moran, P. Raskin, H. Rodriguez, W. E. Russell, D. Schatz, D. Wherrett, D. M. Wilson, J. P. Krischer, J. S. Skyler; Type 1 Diabetes TrialNet Abatacept Study Group, Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 378, 412-419 (2011).
9. V. Viglietta, K. Bourcier, G. J. Buckle, B. Healy, H. L. Weiner, D. A. Hafler, S. Egorova, C. R. G. Guttmann, J. R. Rusche, S. J. Khoury, CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology 71, 917-924 (2008).
10. J. T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D. J. Wallace, S. C. Bae, L. Sigal, J. C. Becker, S. Kelly, K. Raghupathi, T. Li, Y. Peng, M. Kinaszczuk, P. Nash, The efficacy and safety of abatacept in patients with non - life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 3077-3087 (2010).
11. N. J. Felix, A. Suri, L. Salter-Cid, S. G. Nadler, S. Gujrathi, M. Corbo, R. Aranda, Targeting lymphocyte co-stimulation: From bench to bedside. Autoimmunity 43, 514-525 (2010).
12. B. Salomon, J. A. Bluestone, Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
13. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
14. S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
15. A. W. Michels, P. A. Gottlieb, Autoimmune polyglandular syndromes. Nat. Rev. Endocrinol. 6, 270-277 (2010).
16. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, M. K. Levings, Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28-50 (2006).
17. Q. Tang, J. A. Bluestone, Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212, 217-237 (2006).
18. A. H. Banham, Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells. Trends Immunol. 27, 541-544 (2006).
19. + regulatory T cells allows for their purification from expansion cultures. Blood 113, 5125-5133 (2009).
20. + T-regulatory cells: Toward therapy for human diseases. Immunol. Rev. 223, 391-421 (2008).
21. regs) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3, 83ra41 (2011).
22. A. L. Putnam, T. M. Brusko, M. R. Lee, W. Liu, G. L. Szot, T. Ghosh, M. A. Atkinson, J. A. Bluestone, Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58, 652-662 (2009).
23. + T cells. J. Immunol. 177, 944-949 (2006).
24. T. N. Golovina, T. Mikheeva, T. M. Brusko, B. R. Blazar, J. A. Bluestone, J. L. Riley, Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One 6, e15868 (2011).
25. S. L. Bailey-Bucktrout, J. A. Bluestone, Regulatory T cells: Stability revisited. Trends Immunol. 32, 301-306 (2011).
26. X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martínez-Llordella, M. Ashby, M. Nakayama, W. Rosenthal, J. A. Bluestone, Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000-1007 (2009).
27. + regulatory T cells in humans. Proc. Natl. Acad. Sci. U.S.A. 106, 4793-4798 (2009).
28. G. Beriou, C. M. Costantino, C. W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher-Allan, D. A. Hafler, IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240-4249 (2009).
29. + regulatory T cells in human autoimmune disease. Nat. Med. 17, 673-675 (2011).
30. P. Sagoo, N. Ali, G. Garg, F. O. Nestle, R. I. Lechler, G. Lombardi, Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 3, 83ra42 (2011).
31. M. Di Ianni, F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. Ostini, D. Cecchini, T. Aloisi, K. Perruccio, L. Ruggeri, C. Balucani, A. Pierini, P. Sportoletti, C. Aristei, B. Falini, Y. Reisner, A. Velardi, F. Aversa, M. F. Martelli, Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011).
32. F. Aversa, A. Terenzi, A. Tabilio, F. Falzetti, A. Carotti, S. Ballanti, R. Felicini, F. Falcinelli, A. Velardi, L. Ruggeri, T. Aloisi, J. P. Saab, A. Santucci, K. Perruccio, M. P. Martelli, C. Mecucci, Y. Reisner, M. F. Martelli, Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23, 3447-3454 (2005).
33. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E. Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117, 1061-1070 (2011).
34. M. Jutel, C. A. Akdis, Immunological mechanisms of allergen-specific immunotherapy. Allergy 66, 725-732 (2011).
35. F. Meiler, J. Zumkehr, S. Klunker, B. Rückert, C. A. Akdis, M. Akdis, In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887-2898 (2008).
36. C. Ozdemir, U. C. Kucuksezer, M. Akdis, C. A. Akdis, Mechanisms of immunotherapy to wasp and bee venom. Clin. Exp. Allergy 41, 1226-1234 (2011).
37. C. Möbs, C. Slotosch, H. Löffler, T. Jakob, M. Hertl, W. Pfützner, Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J. Immunol. 184, 2194-2203 (2010).
38. J. M. Rolland, L. M. Gardner, R. E. O'Hehir, Functional regulatory T cells and allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 10, 559-566 (2010).
39. C. Ozdemir, U. C. Kucuksezer, M. Akdis, C. A. Akdis, Specific immunotherapy and turning off the T cell: How does it work? Ann. Allergy Asthma Immunol. 107, 381-392 (2011).
40. M. D. Rosenblum, I. K. Gratz, J. S. Paw, K. Lee, A. Marshak-Rothstein, A. K. Abbas, Response to self antigen imprints regulatory memory in tissues. Nature 480, 538-542 (2011).
41. S. Muller, F. Monneaux, N. Schall, R. K. Rashkov, B. A. Oparanov, P. Wiesel, J. M. Geiger, R. Zimmer, Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial. Arthritis Rheum. 58, 3873-3883 (2008).
42. A. W. Michels, G. S. Eisenbarth, Immune intervention in type 1 diabetes. Semin. Immunol. 23, 214-219 (2011).
43. I. Raz, D. Elias, A. Avron, M. Tamir, M. Metzger, I. R. Cohen, β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001).
44. R. Buzzetti, S. Cernea, A. Petrone, M. Capizzi, M. Spoletini, S. Zampetti, C. Guglielmi, C. Venditti, P. Pozzilli; DiaPep Trialists Group, C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: An exploratory study. Diabetes 60, 3067-3072 (2011).
45. M. K. Jenkins, R. H. Schwartz, Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
46. + and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187, 2405-2417 (2011).
47. S. D. Katzman, K. K. Hoyer, H. Dooms, I. K. Gratz, M. D. Rosenblum, J. S. Paw, S. H. Isakson, A. K. Abbas, Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine 56, 116-121 (2011).
48. O. Boyman, M. Kovar, M. P. Rubinstein, C. D. Surh, J. Sprent, Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
49. O. Boyman, C. D. Surh, J. Sprent, Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 6, 1323-1331 (2006).
50. C. L. Liu, P. Ye, B. C. Yen, C. H. Miao, In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol. Ther. 19, 1511-1520 (2011).
51. R. Liu, Q. Zhou, A. La Cava, D. I. Campagnolo, L. Van Kaer, F. D. Shi, Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 40, 1577-1589 (2010).
52. K. E. Webster, S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey, J. Sprent, In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751-760 (2009).
53. Q. Tang, J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, J. A. Bluestone, Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
54. J. Koreth, K. Matsuoka, H. T. Kim, S. M. McDonough, B. Bindra, E. P. Alyea III, P. Armand, C. Cutler, V. T. Ho, N. S. Treister, D. C. Bienfang, S. Prasad, D. Tzachanis, R. M. Joyce, D. E. Avigan, J. H. Antin, J. Ritz, R. J. Soiffer, Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066 (2011).
55. B. D. Hondowicz, K. V. Schwedhelm, A. Kas, M. A. Tasch, C. Rawlings, N. Ramchurren, M. McIntosh, L. A. D'Amico, S. Sanda, N. E. Standifer, J. Shendure, B. Stone, Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 7, e29949 (2012).
56. + regulatory T cells maintain immune homeostasis in the skin. J. Exp. Med. 205, 1559-1565 (2008).
57. M. Müller, S. L. Carter, M. J. Hofer, P. Manders, D. R. Getts, M. T. Getts, A. Dreykluft, B. Lu, C. Gerard, N. J. C. King, I. L. Campbell, CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J. Immunol. 179, 2774-2786 (2007).
58. W. D. James, Andrews' Diseases of the Skin: Clinical Dermatology (Saunders Elsevier, Philadelphia, ed. 10, 2006).
59. L. D. Shultz, F. Ishikawa, D. L. Greiner, Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
60. J. Bathon, M. Robles, A. C. Ximenes, S. Nayiager, J. Wollenhaupt, P. Durez, J. Gomez-Reino, W. Grassi, B. Haraoui, W. Shergy, S. H. Park, H. Genant, C. Peterfy, J. C. Becker, A. Covucci, D. Moniz Reed, R. Helfrick, R. Westhovens, Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann. Rheum. Dis. 70, 1949-1956 (2011).
61. G. Suntharalingam,M. R. Perry, S.Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
62. M. Lebwohl, S. K. Tyring, T. K. Hamilton, D. Toth, S. Glazer, N. H. Tawfik, P. Walicke, W. Dummer, X. Wang, M. R. Garovoy, D. Pariser; Efalizumab Study Group, A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004-2013 (2003).
63. E. Tavazzi, P. Ferrante, K. Khalili, Progressive multifocal leukoencephalopathy: An unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 17, 1776-1780 (2011).
64. D. T. Boumpas, R. Furie, S. Manzi, G. G. Illei, D. J. Wallace, J. E. Balow, A. Vaishnaw; BG9588 Lupus Nephritis Trial Group, A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003).
65. - T regulatory cells. Clin. Immunol. 133, 22-26 (2009).
66. M. Edinger, P. Hoffmann, Regulatory T cells in stem cell transplantation: Strategies and first clinical experiences. Curr. Opin. Immunol. 23, 679-684 (2011).
67. D. K. Wherrett, B. Bundy, D. J. Becker, L. A. DiMeglio, S. E. Gitelman, R. Goland, P. A. Gottlieb, C. J. Greenbaum, K. C. Herold, J. B. Marks, R. Monzavi, A. Moran, T. Orban, J. P. Palmer, P. Raskin, H. Rodriguez, D. Schatz, D. M. Wilson, J. P. Krischer, J. S. Skyler; Type 1 Diabetes TrialNet GAD Study Group, Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 378, 319-327 (2011).